After finishing at $4.38 in the prior trading day, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $4.26, down -2.74%. In other words, the price has decreased by -$0.1200 from its previous closing price. On the day, 1507678 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of ALLO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.58 and its Current Ratio is at 12.58. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On December 08, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $7.Citigroup initiated its Buy rating on December 08, 2023, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 30 ’24 when Parker Geoffrey M. bought 190 shares for $3.60 per share. The transaction valued at 683 led to the insider holds 819,590 shares of the business.
MESSEMER DEBORAH M. sold 18,640 shares of ALLO for $50,317 on Dec 18 ’23. The Director now owns 62,456 shares after completing the transaction at $2.70 per share. On Aug 07 ’23, another insider, Mayo Stephen, who serves as the Director of the company, sold 10,000 shares for $4.29 each. As a result, the insider received 42,855 and left with 25,328 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 720.33M and an Enterprise Value of 366.76M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4502.02 while its Price-to-Book (P/B) ratio in mrq is 1.23. Its current Enterprise Value per Revenue stands at 3.86k whereas that against EBITDA is -1.22.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $6.89, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 4.2898, while the 200-Day Moving Average is calculated to be 3.8893.
Shares Statistics:
The stock has traded on average 2.87M shares per day over the past 3-months and 3.62M shares per day over the last 10 days, according to various share statistics. A total of 144.44M shares are outstanding, with a floating share count of 104.41M. Insiders hold about 38.28% of the company’s shares, while institutions hold 60.85% stake in the company. Shares short for ALLO as of Feb 29, 2024 were 25.01M with a Short Ratio of 8.71, compared to 23.09M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.86% and a Short% of Float of 21.88%.
Earnings Estimates
Its stock is currently analyzed by 12 different market analysts. On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.48, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.23 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.91 and -$2.1 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.54, with 11 analysts recommending between -$0.24 and -$2.2.
